

# Refractory VF and Double Sequential External Defibrillation (DSED)

## Section 1: Case Summary

<b>Scenario Title:</b>	<b>Refractory VF and Double Sequential External Defibrillation (DSED)</b>
Keywords:	Refractory VF, electrical storm, DSED, dual sequential defibrillation, cardiac arrest, ACLS
Brief Description of Case:	A 62-year-old male with a history of ischemic cardiomyopathy presents to the Emergency Department in cardiac arrest with refractory ventricular fibrillation. After standard ACLS interventions fail to terminate VF, the team must recognize refractory VF, coordinate DSED per PHC protocol (Document #B-00-12-10201), and manage post-ROSC care.

Goals and Objectives	
Educational Goal:	To practice the recognition and management of refractory ventricular fibrillation using Double Sequential External Defibrillation (DSED) per PHC protocol, with emphasis on team coordination and communication.
Objectives: (Medical and CRM)	<p><b>Medical Objectives:</b></p> <ul style="list-style-type: none"> <li>• Manage cardiac arrest using standard ACLS algorithms</li> <li>• Recognize refractory VF (persistent VF after 3 consecutive standard defibrillation attempts)</li> <li>• Initiate DSED per PHC protocol: correct pad placement (anterior-lateral + anterior-posterior), "one person, one finger" sequential shock delivery</li> <li>• Verbalize appropriate post-DSED defibrillator testing and BioMed notification</li> <li>• Initiate appropriate post-ROSC care</li> </ul> <p><b>CRM Objectives:</b></p> <ul style="list-style-type: none"> <li>• Effectively lead a resuscitation with multiple team members</li> <li>• Demonstrate clear closed-loop communication during DSED ("shock one" / "shock two")</li> <li>• Assign clear roles: equipment lead, defibrillator operator, compressor, timer</li> <li>• Coordinate team during DSED setup to minimize chest compression interruptions</li> </ul>
EPAs Assessed:	EPA C1 Resuscitation of the critically ill patient EPA C6 Perform procedures relevant to emergency medicine EPA C7 Communication and collaboration in emergency care of patients

Learners, Setting and Personnel			
Target Learners:	<input checked="" type="checkbox"/> Junior Learners	<input checked="" type="checkbox"/> Senior Learners	<input checked="" type="checkbox"/> Staff
	<input checked="" type="checkbox"/> Physicians	<input checked="" type="checkbox"/> Nurses	<input checked="" type="checkbox"/> Inter-professional
	<input type="checkbox"/> Other Learners:		
Location:	<input checked="" type="checkbox"/> Sim Lab	<input checked="" type="checkbox"/> In Situ	<input type="checkbox"/> Other:
Recommended Number of Facilitators:	Instructors: 1		
	Sim Actors: 1		
	Sim Techs: 1		

Scenario Development	
Date of Development:	February 2026
Scenario Developer(s):	Roxanne Robidoux



# Refractory VF and Double Sequential External Defibrillation (DSED)

Affiliations/Institutions(s):	UBC CCFP-EM SPH
Contact E-mail:	robrox01@student.ubc.ca
Last Revision Date:	
Revised By:	
Version Number:	1



# Refractory VF and Double Sequential External Defibrillation (DSED)

## Section 2A: Initial Patient Information

A. Patient Chart					
Patient Name: Robert Chen		Age: 62	Gender: M	Weight: 75 kg	
Presenting complaint: Cardiac arrest – witnessed collapse in ED waiting room					
Temp: 36.2°C	HR: 0	BP: 0/0	RR:	O <sub>2</sub> Sat: 76%	FiO <sub>2</sub> : 1.0
Cap glucose: 6.3 mmol/L			GCS: 3 (E1V1M1)		
Triage note: 62 y/o male presented to triage with chief complaint of substernal chest pressure and diaphoresis for 2 hours. While being registered, patient became unresponsive and collapsed. Bystander (triage nurse) confirmed pulseless – Code Blue called. CPR initiated immediately.					
Allergies: Penicillin (rash)					
Past Medical History: Ischemic cardiomyopathy (EF 35%), prior MI (LAD stent 2021), hypertension, type 2 diabetes, dyslipidemia			Current Medications: ASA 81 mg, ticagrelor 90 mg BID, bisoprolol 5 mg, ramipril 5 mg, atorvastatin 80 mg, metformin 1000 mg BID		

## Section 2B: Extra Patient Information

A. Further History	
<b>Clinical Vignette – To Read Aloud at Beginning of Case:</b>	
<b>"Code Blue, Emergency Department, Resuscitation Bay 1."</b> A 62-year-old male collapsed in the ED waiting room about 2 minutes ago. The triage nurse confirmed he was pulseless and started CPR. He was brought into the resuscitation bay on a stretcher. He had been complaining of chest pressure for the past 2 hours. CPR is ongoing.	
From Wife (if asked):	
<ul style="list-style-type: none"><li>• Husband had an MI in 2021, stent placed at SPH</li><li>• Recently told by cardiologist his heart function is reduced (EF 35%)</li><li>• Was supposed to get an ICD but was still on the waitlist</li><li>• No recent illness, no drug use, no toxic ingestion</li><li>• She is unsure of his exact medication but says he takes blood thinners and blood pressure pills</li><li>• Code Status: Full Code</li></ul>	
B. Physical Exam	
General: Unresponsive, pulseless, apneic. Pale, diaphoretic.	
Cardio: No heart sounds. VF on monitor. No pulse with CPR pause.	Neuro: GCS 3. Pupils 6 mm, fixed bilaterally.
Resp: No spontaneous respirations. Bilateral air entry with BVM.	Head & Neck: No trauma. No JVD appreciable.
Abdo: Soft, non-distended.	MSK/skin: Pale, cool, mottles. No scars on chest (no sternotomy scar). Small scar right groin (prior cath).
Other:	



# Refractory VF and Double Sequential External Defibrillation (DSED)

## Section 3: Technical Requirements/Room Vision

A. Patient
<input checked="" type="checkbox"/> Mannequin ( <i>High-fidelity adult mannequin capable of displaying cardiac rhythms and accepting defibrillator pad placement</i> )
<input type="checkbox"/> Standardized Patient
<input type="checkbox"/> Task Trainer
<input type="checkbox"/> Hybrid
B. Special Equipment Required
<ul style="list-style-type: none"><li>• <b>TWO defibrillators (Zoll R-Series and/or X-Series) – both functional with adequate battery</b></li><li>• <b>TWO sets of defibrillator pads</b></li><li>• NIBP Cuff, Pulse Oximeter, Temperature Probe</li><li>• Standard crash cart with ACLS medications, IV Bags/Lines</li><li>• BVM, oral/nasal airways, intubation equipment (laryngoscope, VL, ETT, LMA)</li><li>• IV supplies, IO kit</li><li>• EKG Leads/Wires</li><li>• Backboard/CPR compression device if available</li><li>• DSED Infographic (PHC version) – printed and posted in resus bay</li></ul>
C. Required Medications
Epinephrine, Amiodarone, Esmolol, Lidocaine, Magnesium sulfate, Sodium bicarbonate, Normal saline 1L bags (x2)
D. Moulage
Diaphoretic skin (water spray). Small scar right groin (drawn with marker).
E. Monitors at Case Onset
<input type="checkbox"/> Patient on monitor with vitals displayed
<input checked="" type="checkbox"/> Patient not yet on monitor
F. Patient Reactions and Exam
General: Unresponsive, pulseless, apneic. Pale, diaphoretic. Airway/Breathing: no spontaneous respirations → bilateral air entry if BVM initiated Circulation: absent heart sounds, pulseless Disability: GCS 3 Exposure: euglycemic, normothermic, no visible signs of trauma
Once patient is placed on monitors, VF should display. Defibrillator #1 at bedside with pads to be placed in standard anterior-lateral position. Defibrillator #2 available but NOT yet at bedside (must be requested/retrieved).



# Refractory VF and Double Sequential External Defibrillation (DSED)

## Section 4: Sim Actor and Standardized Patients

Sim Actor and Standardized Patient Roles and Scripts	
None	N/A



# Simulation Scenario Template

## Section 5: Scenario Progression

Scenario States, Modifiers and Triggers				
Patient State/Vitals	Patient Status	Learner Actions, Modifiers & Triggers to Move to Next State	Facilitator Notes	
<b>1. Baseline State</b> Rhythm: VF HR: 0 BP: 0/0 RR: 0 O <sub>2</sub> SAT: 76% with CPR ETCO <sub>2</sub> : 21 T: 36.2°C GCS: 3	Unresponsive, pulseless, apneic.	<u>Expected Learner Actions</u> <input type="checkbox"/> Confirm pulselessness, initiate/continue high-quality CPR <input type="checkbox"/> Attach monitor, confirm VF <input type="checkbox"/> Defibrillate at 200J (biphasic) <input type="checkbox"/> Establish IV/IO access <input type="checkbox"/> Epinephrine 1 mg IV q3-5 min <input type="checkbox"/> Amiodarone 300 mg IV after 3rd shock <input type="checkbox"/> BVM ventilation ± advanced airway <input type="checkbox"/> Consider reversible causes (Hs and Ts) and send for labs <input type="checkbox"/> Bedside echo if available	<u>Modifiers</u> - Patient remains in VF regardless of standard defibrillation or medications given. - Rhythm briefly organizes to coarse VF after each shock then returns to fine VF. <u>Triggers</u> - After 3 consecutive defibrillation attempts + amiodarone → <b>progress to State 2: Refractory VF</b>	
<b>2. Refractory VF</b> Unchanged	Unchanged. Persistent VF.	<u>Expected Learner Actions</u> <input type="checkbox"/> Recognize refractory VF after 3 consecutive shocks → Prepare for DSED → Request 2 <sup>nd</sup> defibrillator to bedside and apply 2 <sup>nd</sup> set of pads <input type="checkbox"/> Pad placement: Set 1 anterior-lateral, Set 2 anterior-posterior (preferred) – no overlap <input type="checkbox"/> <b>Assign single operator for both defibrillators ("one person, one finger")</b>	<u>Modifiers</u> - VF persists until DSED is correctly performed. - If pads placed overlapping, prompt team to readjust <u>Triggers</u> - <b>The first DSED attempt will NOT achieve ROSC (VF persists after first DSED, requiring 2 attempts before ROSC → after 2 attempts with DSED correctly performed (sequential shocks,</b>	- If learners not yet considering DSED after 4th shock, Facilitatory should bring out infographic on DSED and say <i>"I just found this info- have you thought about it?"</i> - After 3 doses of epinephrine (3mg total), consider holding further epinephrine and pivoting to esmolol (see discussion notes for details on epinephrine ceiling dose)



# Simulation Scenario Template

		<input type="checkbox"/> At rhythm check: Leader orders energy level (e.g., "200J on each") → charge both → clear patient (visually confirms) <input type="checkbox"/> <b>Deliver Shock 1 → announce "Shock One" → Immediately deliver Shock 2 → announce "Shock Two"</b> <input type="checkbox"/> Resume CPR immediately after 2 <sup>nd</sup> shock	<p>proper pad placement) → <b>Progress to State 3: ROSC</b></p> <p>- If no DSED after 6 total shocks → <b>Progress to State 4: Deterioration (Asystole)</b></p>	<p><u>Esmolol:</u></p> <ul style="list-style-type: none"> <li>- Loading dose: 500 mcg/kg IV bolus</li> <li>- Infusion: 0–100 mcg/kg/min, titrate to effect</li> <li>- Onset &lt;60 seconds, half-life ~9 minutes</li> <li>- Expected post-ROSC BP effect: hypotension likely; manage with norepinephrine; stop infusion if severe (effects self-resolve in 10–30 min)</li> <li>- If BP is labile: stop infusion (no taper needed), support with vasopressors; short half-life is the safety net</li> <li>- Post-ROSC: may continue low-rate infusion to prevent re-fibrillation; titrate down as patient stabilizes</li> </ul> <p>Labs results pending.</p>
<p><b>3. ROSC</b>          Rhythm: Sinus Tach          HR: 105          BP: 95/58          RR: 14 (vent)          O<sub>2</sub>SAT: 94%          T: 36.2°C          ETCO<sub>2</sub>: 35</p>	<p>Color improves.          Palpable pulse.          Remains unresponsive.</p>	<p><u>Expected Learner Actions</u></p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Confirm pulse and BP</li> <li><input type="checkbox"/> 12-lead ECG (and 15-lead)</li> <li><input type="checkbox"/> Intubate if not yet done</li> <li><input type="checkbox"/> Post-intubation CXR</li> <li><input type="checkbox"/> Initiate targeted temperature management</li> <li><input type="checkbox"/> Vasopressors for MAP &gt; 65 (norepinephrine)</li> <li><input type="checkbox"/> Activate cath lab, ICU, CCU</li> </ul>	<p><u>Modifiers</u></p> <ul style="list-style-type: none"> <li>- ECG shows anterior STEMI</li> </ul> <p><u>Triggers</u></p> <ul style="list-style-type: none"> <li>- <b>All post-ROSC actions complete OR 15 min elapsed → End of Case ("Cath lab is ready for the patient")</b></li> <li>- If time permitting → <b>optional branch point to 3A. Pseudo-PEA post ROSC</b></li> </ul>	<p><u>Labs results available</u></p>



# Simulation Scenario Template

		<input type="checkbox"/> Sedation and analgesia		
<b>3A. Pseudo-PEA</b> Rhythm: organized	Loss of palpable pulse post-ROSC.	<u>Expected Learner Actions</u> <input type="checkbox"/> Perform POCUS to assess for cardiac activity <input type="checkbox"/> Use Doppler or arterial lines to detect low-flow state <input type="checkbox"/> Distinguish pseudo-PEA (PREM) from true PEA (PRES) <input type="checkbox"/> Treat as profound shock with titratable vasopressors rather than epi boluses <input type="checkbox"/> Search for reversible causes	<u>Modifiers</u> - If carotid Doppler shows low flow → confirm pseudo-PEA, consider pausing CPR, initiate vasopressor infusion and volume  - If echo shows contractions but no Doppler flow → true PEA, continue CPR and aggressively treat reversible causes	<b>Optional branch after ROSC:</b> The patient transiently develops an organized rhythm without a palpable pulse post-ROSC.
<b>4. Deterioration</b> (if DSED not performed) Rhythm: Asystole HR: 0 BP: 0/0 ETCO2: 5	Non-responsive. No pulse.	<u>Expected Learner Actions</u> <input type="checkbox"/> Continue epinephrine 1mg q3-5 min <input type="checkbox"/> Consider termination of resuscitation	<u>Modifiers</u> - - -  <u>Triggers</u> - -	End case. Debrief on missed DSED opportunity.



# Simulation Scenario Template

## Appendix A: Laboratory Results


<p><u>CBC</u> WBC 12.5 Hgb 142 Plt 225</p> <p><u>Lytes</u> Na 139 K 4.2 Cl 102 HCO<sub>3</sub> 16 Cr 96 Glucose 14.2</p> <p><u>Extended Lytes</u> Ca 2.25 Mg 0.82 PO<sub>4</sub> 1.2 TSH 4</p> <p><u>VBG</u> pH 7.18 pCO<sub>2</sub> 52 pO<sub>2</sub> 45 HCO<sub>3</sub> 16 Lactate 8.5</p>	<p><u>Cardiac/Coags</u> Trop 450 ng/L D-dimer INR 1.0 aPTT 28</p> <p><u>Biliary:</u> pending AST ALT GGT ALP Bili Lipase</p> <p><u>Tox:</u> pending EtOH ASA Tylenol Dig level Osmols</p>
--	---



# Simulation Scenario Template

## Appendix B: ECGs, X-rays, Ultrasounds and Pictures


### ECG (Post-ROSC): Anterior STEMI



Source: <https://litfl.com/anterior-myocardial-infarction-ecg-library/> Example 8: <https://litfl.com/wp-content/uploads/2018/08/ECG-Ostial-LAD-occlusion-septal-STEMI-2.jpg>

# Simulation Scenario Template

CXR (Post-Intubation): Normal ETT placement, no pneumothorax.




Source: <https://emsimcases.com/wp-content/uploads/2015/11/normal-post-intubation-cxr.png>

PHC DSED Infographic (Print and have available to provide to a copy to learners during the simulation):


## SPH/MSJ

# DUAL SEQUENTIAL EXTERNAL DEFIBRILLATION (DSED)


### CONSIDER DSED IF:



Cardiac arrest with **refractory ventricular fibrillation**




At least **3 consecutive defibrillation attempts**  
(with appropriate ACLS medications administered)




Attempted to **change electrical vector**  
(e.g. consider AP placement if starting with AL placement)


YOU WILL NEED



Two **defibrillators** and two **defibrillator pads**  
*Either 2 R-Series, 2 X-Series, or a combination of the two*




“One person, one finger” for both defibrillators  
*A second operator is only used if it's not possible to position both defibrillators near each other*



**Antero-lateral + antero-posterior (AL-AP) preferred**


**Ensure pads do not touch or overlap**



If unable to do AL-AP, then antero-lateral + antero-lateral is also acceptable.


### PROCEDURE

**CLEAR PATIENT**

Machine #1  
 **Give first shock**


Say: Shock ONE

**THEN IMMEDIATELY**

Machine #2  
 **Give second shock**

Say: Shock TWO

### AFTER USE



1. Do a **30J manual test** on each defibrillator.
2. **Visually inspect** each defibrillator for damage.
3. Follow department-specific process to **report defibrillators to BioMed** for additional inspection.



# Simulation Scenario Template

## Appendix C: Facilitator Cheat Sheet & Debriefing Tips

Include key errors to watch for and common challenges with the case. List issues expected to be part of the debriefing discussion. Supplemental information regarding any relevant pathophysiology, guidelines, or management information that may be reviewed during debriefing should be provided for facilitators to have as a reference.

### Key Errors to Watch For:

- Delivering simultaneous shocks instead of sequential shocks (must be rapid succession, NOT simultaneous)
- Overlapping defibrillator pads between the two sets
- Using two operators when defibrillators can be positioned side-by-side ("one person, one finger" preferred)
- Failing to verbally clear the patient before DSED shock delivery
- Prolonged chest compression pauses during DSED setup
- Attempting DSED before 3 consecutive standard defibrillation attempts
- Forgetting post-DSED defibrillator testing (manual self-test + visual inspection) and BioMed notification

### DSED Quick Reference (per PHC Protocol #B-00-12-10201):

- Indicated for: Refractory VF after 3 consecutive shocks + high-quality CPR + appropriate pharmacotherapy
- Requires: 2 defibrillators, 2 sets of pads, ACLS-trained personnel
- Pad placement: Set 1 = anterior-lateral; Set 2 = anterior-posterior (preferred) or anterior-lateral (alternate). No overlap.
- Operator: Single designated person operates both defibrillators ("one person, one finger")
- Delivery: Shock 1 → "Shock One" → immediately Shock 2 → "Shock Two" → resume CPR

### Sample Debriefing Questions:

- When did you first recognize this was refractory VF? What prompted you to consider DSED?
- Walk me through how you set up for DSED. What went well? What would you change?
- How did the team coordinate pad placement while minimizing compression pauses?
- Describe the "one person, one finger" principle. Why is sequential (not simultaneous) delivery important?
- What additional pharmacological strategies exist for refractory VF beyond DSED?

- Walk us through the esmolol dosing you would use. What would you do if the patient's BP dropped after ROSC while on an esmolol infusion?

- Esmolol in Refractory VF: Evidence Summary.

- The following table summarises the key studies and current guideline recommendations for esmolol use in refractory ventricular fibrillation. Evidence remains limited to small retrospective studies and one pilot RCT; larger prospective trials are ongoing.

Esmolol in Refractory VF: Evidence Summary			
Study	Design	Esmolol Dose	Key Findings
Driver et al. 2014 <i>Resuscitation</i>	Retrospective, single-centre	500 mcg/kg bolus + 0–100 mcg/kg/min infusion	<b>Sustained ROSC:</b> 67% vs 32% <b>Survival to discharge:</b> 50% vs 16% <b>Good neuro outcome:</b> 50% vs 11%
Lee et al. 2016 <i>Resuscitation</i>	Retrospective pre-post, single-centre (Korea)	500 mcg/kg bolus + 0–100 mcg/kg/min infusion	<b>Sustained ROSC:</b> 56% vs 16% (p=0.007) <b>Good neuro outcome:</b> 19% vs 8% (NS)
Patrick et al. 2022 <i>JACEP Open</i>	Retrospective before-and-after, EMS feasibility	0.5 mg/kg single bolus (no infusion)	<b>Feasibility:</b> 87% of eligible patients received esmolol <b>Prehospital ROSC:</b> 52% vs 44% (NS) <b>Survival to discharge:</b> NS



# Simulation Scenario Template

<b>Stupca et al. 2023</b> <i>Am J Emerg Med</i>	Retrospective multi-centre cohort	40 mg fixed bolus + epi cap 3 mg + vector change (EMS bundle)	<b>Sustained ROSC:</b> Lower in bundle group <b>Neuro-intact survival:</b> Similar between groups <b>Note:</b> Fixed (non-weight-based) esmolol dose may have been inadequate
<b>BETA-ARREST</b> 2024 <i>Resuscitation</i> (Schriebl et al.)	Prospective RCT, double-blind, placebo-controlled (pilot)	Landiolol 20 mg bolus (not esmolol; ultra-short beta-1 blocker)	<b>First prospective RCT of beta-blockade in refractory VF</b> No benefit demonstrated for time to ROSC <b>Key caveats:</b> different drug (landiolol), no infusion, small pilot study, broader VF definition
<b>REVIVE 2025</b> <i>Resusc Plus</i>	Multi-centre collaborative (UK); pilot RCT planned	Esmolol + de-emphasised adrenaline (protocol in development)	<b>Ongoing:</b> 3-phase project (national survey, registry review, pilot RCT) Rationale: combines sympatholysis (esmolol) with reduced catecholamine load

## 2025 AHA ACLS Guidelines — Beta-Blockers for Refractory VF/pVT

**Recommendation:** "Use of beta-blockers, bretylium, procainamide, or sotalol for refractory VF/pVT is of uncertain benefit."

**Class of Recommendation:** 2b (Weak) | **Level of Evidence:** C-LD (Limited Data)

**Clinical implication:** May be considered as a "kitchen sink" adjunct when standard ACLS + amiodarone + DSED have failed. Ultra-short half-life (~9 min) provides a built-in safety net. Larger RCTs (REVIVE) are ongoing.

## Esmolol Quick-Reference Dosing for Refractory VF

Loading Dose	Infusion	Onset / Half-Life	Post-ROSC BP Management
<b>500 mcg/kg IV bolus</b> (~37.5 mg for 75 kg)	<b>0–100 mcg/kg/min</b> Titrate to rhythm stability <i>Some protocols: bolus only (no infusion)</i>	<b>Onset: &lt;60 sec</b> Half-life: ~9 min Steady state: 2 min (with loading dose)	<b>If hypotensive:</b> STOP infusion (no taper) Effects resolve in 10–30 min Support with norepinephrine <b>Labile BP is manageable; short t<sub>1/2</sub> is the safety net</b>

- How many doses of epinephrine were given? At what point, if any, would you consider capping epinephrine? What does the evidence say?
  - Emerging evidence suggests cumulative epi >3 mg is associated with worse neurological outcomes (Garcia et al., *Am J Emerg Med*, 2024). Current AHA guidelines do not define a formal ceiling but recommend against high-dose epi and note increasing evidence of harm from excessive catecholamine exposure in refractory shockable rhythms.
- What are the post-DSED equipment responsibilities per PHC protocol?
- If after ROSC the patient lost their pulse again with an organized rhythm on the monitor, how would you use POCUS to distinguish pseudo-PEA from true PEA? How would your management differ?
  - Pseudo-PEA / PREM Teaching Points

## Pseudo-PEA (PREM) vs. True PEA (PRES): Definitions, Diagnosis & Management

Feature	Pseudo-PEA / PREM ( <i>Pulseless, Rhythm, Echo Motion</i> )	True PEA / PRES ( <i>Pulseless, Rhythm, Echo Standstill</i> )
<b>Definition</b>	Organized electrical activity on monitor + cardiac contractile activity on POCUS + no palpable pulse. A profound shock state, <b>NOT</b> true cardiac arrest.	Organized electrical activity on monitor + <b>NO</b> cardiac contractile activity on POCUS + no palpable pulse. <b>True</b> electromechanical dissociation.
<b>POCUS Cardiac</b>	Coordinated ventricular contractions visible with LV volume change (organized activity)	Cardiac standstill, or only agonal/disorganized twitching without effective ventricular contraction
<b>Carotid Doppler</b>	Low-flow pulsatile signal detectable (may detect flow at SBP as low as 19 mmHg — Faldaas et al. 2023)	No pulsatile flow detected
<b>Other Indicators</b>	May see: ETCO <sub>2</sub> >20 mmHg, SpO <sub>2</sub> waveform present, arterial line pulsations	ETCO <sub>2</sub> typically <10 mmHg, no SpO <sub>2</sub> waveform, flat arterial line tracing



# Simulation Scenario Template

<b>Prognosis</b>	ROSC 70–94%; ~50% good neurological outcome (Prosen et al. 2010)	Survival to discharge 0–6% (Gaspari et al., REASON trial)
<b>Management</b>	<b>Treat as PROFOUND SHOCK:</b> <ul style="list-style-type: none"><li>• Consider pausing CPR (compressions during contractility may impair output)</li><li>• IV fluid bolus</li><li>• Titratable vasopressor: norepinephrine infusion or push-dose epi (10–20 mcg) — <b>NOT 1 mg epi boluses</b></li><li>• Place arterial line (top priority)</li><li>• Aggressively treat reversible causes (Hs &amp; Ts)</li><li>• Reassess frequently with POCUS</li></ul>	<b>Treat as TRUE CARDIAC ARREST:</b> <ul style="list-style-type: none"><li>• Continue high-quality CPR</li><li>• Epinephrine 1 mg IV q3–5 min per ACLS</li><li>• Aggressively search for and treat reversible causes</li><li>• POCUS: tamponade, RV strain (PE), hypovolemia, pneumothorax</li><li>• Consider early termination if cardiac standstill persists</li><li>• Prognosis is poor if no activity found on serial POCUS</li></ul>

## Key Concept: The POCUS Pulse Check

**Manual pulse palpation is unreliable:** up to 45% of providers cannot accurately detect a central pulse during CPR (Eberle et al. 1996). Up to 32% of PEA diagnoses are inaccurate — patients have detectable circulation missed by palpation (Zengin et al. 2018).

**POCUS pulse check:** Place a linear probe over the carotid (or femoral) artery in short axis. Pulsatile Doppler flow during a pause in compressions indicates cardiac output is present, even if a manual pulse is not palpable. Can be completed accurately in <5 seconds with minimal training (Simard et al., The POCUS Pulse Check).

### Decision framework (from EM Cases Ep. 131, Simard & Weingart):

1. POCUS cardiac: Is the heart contracting? → If NO = PRES (true PEA). If YES, proceed to step 2.
2. POCUS pulse (carotid/femoral Doppler): Is there detectable flow? → If YES = PREM (pseudo-PEA). If NO with echo motion = consider true PEA with agonal activity.
3. Corroborate with ETCO<sub>2</sub> (>20 mmHg suggests output), SpO<sub>2</sub> waveform, and arterial line if available.

## Key Debriefing Moments:

- Recognition of refractory VF and decision to escalate to DSED
- Correct DSED procedure: pad placement, "one person, one finger," sequential shock delivery with verbal announcements
- Team role assignment and closed-loop communication during DSED
- Post-ROSC care: ECG interpretation (STEMI), cath lab activation, TTM initiation



# Simulation Scenario Template

## References

1. Berg, K.M., Bray, J.E., Ng, K.C., et al. (2024). 2023 International Consensus on CPR and ECC Science With Treatment Recommendations. *Resuscitation*, 195, 109992.
2. Cheskes, S., Verbeek, P.R., Drennan, I.R., et al. (2022). Defibrillation Strategies for Refractory Ventricular Fibrillation. *NEJM*, 387(21), 1947-1956.
3. Cheskes, S.M.D., & McLeod, S.L.P. (2025). Double sequential external defibrillation for refractory ventricular fibrillation: the science, the controversies and the future. *Journal of Electrocardiology*, 91, 154046.
4. Deakin, C.D., Morley, P., Soar, J., & Drennan, I.R. (2020). Double (dual) sequential defibrillation for refractory ventricular fibrillation cardiac arrest: A systematic review. *Resuscitation*, 155, 24-31.
5. Driver, B.E., et al. (2014). Use of esmolol after failure of standard CPR to treat patients with refractory VF. *Resuscitation*, 85(10), 1387-1389.
6. Faldaas, B.O., et al. (2023). Hands-free continuous carotid Doppler US for detection of pulse during cardiac arrest. *Resusc Plus*, 15, 100412.
7. Garcia, S.I., et al. (2024). Cumulative epinephrine dose during cardiac arrest and neurologic outcome after ECPR. *Am J Emerg Med*, 80, 61-66.
8. Gaspari, R., et al. (2017). A retrospective study of PEA, bedside US identifies interventions associated with improved survival. *Resuscitation*, 120, 103-109.
9. Helman, A., Simard, R., & Weingart, S. (2022). PEA Arrest, PseudoPEA and PREM. *EM Cases Episode* 131.
10. Lee, Y.H., et al. (2016). Refractory ventricular fibrillation treated with esmolol. *Resuscitation*, 107, 150-155.
11. Long, B.M.D., & Gottlieb, M.M.D. (2025). Emergency medicine updates: Defibrillation strategies in cardiac arrest. *Am J Emerg Med*, 95, 57-62.
12. Magon, F., et al. (2024). POCUS in Adult Cardiac Arrest: Clinical Review. *Diagnostics*, 14(4), 434.
13. Patrick, C., et al. (2022). Feasibility of prehospital esmolol for refractory VF. *JACEP Open*, 3(2), e12700.
14. Prosen, G., et al. (2010). Impact of modified treatment in echocardiographically confirmed pseudo-PEA in OHCA. *J Int Med Res*, 38(4), 1458-1467.
15. Providence Health Care. (2025). Double Sequential External Defibrillation (DSED) for Refractory Ventricular Fibrillation. Procedure Document #B-00-12-10201. Effective 18-DEC-2025.
16. Rabjohns, J., et al. (2020). Pseudo-pulseless electrical activity in the ED, an evidence-based approach. *Am J Emerg Med*, 38, 371-375.
17. REVIVE Project. (2025). Esmolol in persistent VF/VT with de-emphasised adrenaline. *Resusc Plus*, 21, 100855.
18. Schriefel, C., et al. (2024). (BETA-ARREST) Landiolol for refractory VF in OHCA: A randomized, double-blind, placebo-controlled pilot trial. *Resuscitation*, 201, 110166.
19. Simard, R.D., et al. (2019). The POCUS Pulse Check: A Novel Method for Determining the Presence of a Pulse Using POCUS. *Can J Emerg Med*.
20. Stupca, K., et al. (2023). Esmolol, vector change, and dose-capped epinephrine for prehospital VF/pVT. *Am J Emerg Med*, 64, 46-50.
21. Tessier, W., Blais, S., Provost, J., & Ouellet, S. (2025). Double external defibrillation in the emergency department: A rapid review. *CJEN*, 48(2), 47-55.
22. Watson, A., et al. (2024). Outcomes of a 'de-emphasised' adrenaline strategy for refractory VF. *Resusc Plus*, 19, 100716.
23. Yu, J.M.P.H., et al. (2024). Defibrillation strategies for patients with refractory ventricular fibrillation: A systematic review and meta-analysis. *Am J Emerg Med*, 84, 149-157.
24. Zengin, S., et al. (2018). Comparison of manual pulse palpation, cardiac US and Doppler US to check the pulse in CPR patients. *Resuscitation*, 133, 59-64..

